Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akero Therapeutics Inc (NQ: AKRO )

27.20 +0.31 (+1.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 484,641
Open 26.95
Bid (Size) 27.18 (8)
Ask (Size) 27.21 (35)
Prev. Close 26.89
Today's Range 26.32 - 27.50
52wk Range 11.25 - 53.77
Shares Outstanding 50,086,978
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
AKERO THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKRO
From Kahn Swick & Foti, LLC
Via Business Wire

Performance

YTD
+15.84%
+15.84%
1 Month
+1.76%
+1.76%
3 Month
+44.53%
+44.53%
6 Month
-2.19%
-2.19%
1 Year
-45.19%
-45.19%

More News

Read More
AKRO Stock Earnings: Akero Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Akero Therapeutics Inc.
Via GlobeNewswire
This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges
Via Benzinga
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)
From The Law Offices of Frank R. Cruz
Via Business Wire
AKRO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – AKRO
From The Rosen Law Firm PA
Via GlobeNewswire
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
AKERO THERAPEUTICS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO
From Kahn Swick & Foti, LLC
Via Business Wire
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – AKRO
From The Rosen Law Firm PA
Via GlobeNewswire
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit
From The Rosen Law Firm PA
Via GlobeNewswire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
From Akero Therapeutics Inc.
Via GlobeNewswire
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.